Short interest in Cassava Sciences Inc (NASDAQ:SAVA) decreased during the last reporting period, falling from 15.94M to 14.45M. This put 32.04% of the company's publicly available shares short.
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback